PRF Technologies (PRFX) exec chair discloses vested stock option positions

Rhea-AI Filing Summary

PRF Technologies Ltd. executive chairman Ehud Geller filed an initial Form 3 showing his derivative holdings in employee stock options over ordinary shares. The filing lists several option grants under the 2019 PainReform Option Plan, fully vested on their respective grant dates, with exercise prices ranging from 0.0500 to 5400.0000 and expirations between 2031 and 2035. These entries reflect existing option positions rather than new purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GELLER EHUD

(Last) (First) (Middle)

C/O PRF TECHNOLOGIES LTD.

65 YIGAL ALON ST.

(Street)

TEL AVIV 6744316

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PRF Technologies Ltd. [ PRFX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec Chairman of the Board

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	(3)	02/23/2031	Ordinary Shares	50	$5,400	D
Employee Stock Option (Right to Buy)(1)(2)	(4)	07/18/2034	Ordinary Shares	1,219	$30	D
Employee Stock Option (Right to Buy)(1)(2)	(5)	10/10/2034	Ordinary Shares	183	$30	D
Employee Stock Option (Right to Buy)(1)(2)	(6)	02/20/2035	Ordinary Shares	20,314	$0.05	D
Employee Stock Option (Right to Buy)(1)(2)	(7)	06/08/2033	Ordinary Shares	150	$706.8	D

Explanation of Responses:

1. Options granted under the 2019 PainReform Option Plan.

2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.

3. The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.

4. The grant date of this grant is July 18, 2024. This option grant is fully vested as of this date.

5. The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date.

6. The grant date of this grant is February 20, 2025. This option grant is fully vested as of this date.

7. The grant date of this grant is June 8, 2023. 144 of the options were vested as of the date of appointment. The remaining 6 options will vest on June 8, 2026, subject to the Reporting Person?s continued service to the Issuer as of such date.

	/s/ Ehud Geller	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the PRFX Form 3 filed by Ehud Geller show?

The Form 3 shows Ehud Geller’s existing holdings of employee stock options over PRF Technologies ordinary shares. It lists multiple fully vested grants under the 2019 PainReform Option Plan, detailing exercise prices, underlying share amounts and option expiration dates, but no new purchases or sales.

Does the PRFX Form 3 indicate that Ehud Geller bought or sold shares?

No. The Form 3 lists option holdings only, with transactions classified as “holding” and no buy or sell codes. It describes pre-existing employee stock option grants, including their exercise prices and expiration dates, rather than any open-market share purchases or sales.

What types of securities are reported in the PRFX Form 3?

The filing reports Employee Stock Options (Right to Buy) linked to PRF Technologies ordinary shares. Each line shows an option grant’s underlying share amount, exercise price, expiration date and vesting status, all held directly by Ehud Geller as part of his compensation.

Are the stock options in the PRFX Form 3 vested?

Yes, the footnotes state that option grants dated February 23 2021, July 18 2024, October 10 2024 and February 20 2025 are fully vested. A June 8 2023 grant is mostly vested, with a small remaining portion scheduled to vest on June 8 2026.

Under which plan were Ehud Geller’s PRFX options granted?

The options were granted under the 2019 PainReform Option Plan. Footnotes explain that, to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee under this plan must be registered in the name of a trustee.

How long do Ehud Geller’s PRFX options remain exercisable?

The options reported have expiration dates ranging from 2031-02-23 to 2035-02-20, depending on the specific grant. This gives a multi‑year window during which Geller may exercise these rights to buy PRF Technologies ordinary shares at the stated exercise prices.